Business
Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study
Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nPan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study\n\n\n\n\n\nPan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study\nStudy indicates that HemaXellerate appears to demonstrate safety and efficacy in patients suffering chemotherapy induced bone marrow suppression\nPR Newswire\nSAN DIEGO, October 24, 2016\n\n\n\nSAN DIEGO, October 24, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico presented final clinical data on their first 5 patients.  Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided.  Pan Am Cancer Treatment Center has now provided 3 and 6 month follow up data in these same patients.  The primary endpoint of the study is safety and the secondary endpoint is effectiveness. Pan Am Cancer Treatment Center has been granted  a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study.\n\nWith regards to safety, none of the 5 patients experienced any adverse events.  In other words, all of the patients tolerated HemaXellerate with no side-effects. Effectiveness was measured by taking blood tests of the patients 1, 3 and 6 months post-HemaXellerate treatment and measuring the levels of blood cells, particularly immune cells, circulating in their blood.  As previously presented, at 1 month post-HemaXellerate treatment, 2 patients (40%) had a dramatic increase in their circulating white blood cells to levels even above the normal range and all other patients had their white blood cells return to the normal range.\n\nIn the latest data presented, the patients who apparently benefited after one month maintained their high levels of white blood cells and all 5 patients had increased numbers of white blood cells after 6 months as compared to after 1 month.  In addition, all 5 patients had increased numbers of red blood cells and increased numbers of platelets 6 months after treatment as compared to after 1 month.\n\n\"These data are interesting.  While there is...